Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF OPERATING OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 16,307 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,477 · Balance 14,506 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,611 · Balance 16,117 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,740 · Balance 17,857 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,457 · Balance 20,314 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,007 · Balance 16,307 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 9,250 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 9,250 · Balance 9,250 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,371 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 2,457 · Balance 7,371 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,481 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,740 · Balance 3,481 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,611 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,611 · Balance 1,611 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,477 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 36,950 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 36,950 · Balance 36,950 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · derivative · entry 11 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 2,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · derivative · entry 10 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,611 Underlying: Class A Ordinary Share · 1,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · derivative · entry 9 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,481 Underlying: Class A Ordinary Share · 1,740 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · derivative · entry 8 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,371 Underlying: Class A Ordinary Share · 2,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 36,950 | $0.00 Strike: $79.28 | $0.00 |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · derivative · entry 7 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,950 Underlying: Class A Ordinary Share · 36,950 shares Expires 2036-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · derivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 Underlying: Class A Ordinary Share · 9,250 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 4,007 | $79.28 | $317,674.96 |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · nonDerivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,307 Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · nonDerivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,740 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,611 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001857177-26-000008 · form4-09032026_080952.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 1,703 | $46.69 | $79,513.07 |
DisclosureSEC source: 0001857177-26-000006 · form4-04132026_080438.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,029 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000004 · form4-04082026_080439.xml · derivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 2,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 774 | $48.94 | $37,879.56 |
DisclosureSEC source: 0001857177-26-000004 · form4-04082026_080439.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,732 Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001857177-26-000004 · form4-04082026_080439.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 2,367 | $48.58 | $114,988.86 |
DisclosureSEC source: 0001857177-26-000004 · form4-04082026_080439.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,029 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000002 · form4-04032026_080450.xml · derivative · entry 9 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,371 Underlying: Class A Ordinary Share · 2,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F9 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. F9 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000002 · form4-04032026_080450.xml · derivative · entry 8 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,481 Underlying: Class A Ordinary Share · 1,740 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2024. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000002 · form4-04032026_080450.xml · derivative · entry 7 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161 Underlying: Class A Ordinary Share · 1,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000002 · form4-04032026_080450.xml · derivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Class A Ordinary Share · 18,500 shares Expires not disclosed F5 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F6 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. F6 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001857177-26-000002 · form4-04032026_080450.xml · derivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 Underlying: Class A Ordinary Share · 9,250 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 36,950 | $0.00 Strike: $48.13 | $0.00 |
DisclosureSEC source: 0001857177-26-000002 · form4-04032026_080450.xml · derivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,950 Underlying: Class A Ordinary Share · 36,950 shares Expires 2036-03-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,706 | $48.13 | $82,109.78 |
DisclosureSEC source: 0001857177-26-000002 · form4-04032026_080450.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,396 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 5,808 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001857177-26-000002 · form4-04032026_080450.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| January 15, 2026 Filed Apr 3, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Ordinary Share | 879 | $24.16 | $21,236.64 |
DisclosureSEC source: 0001857177-26-000002 · form4-04032026_080450.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,294 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2025 to January 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 3,523 | $35.31 | $124,397.13 |
DisclosureSEC source: 0001415889-25-023874 · form4-09082025_080945.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,415 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · derivative · entry 12 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 481 | $34.28 | $16,488.68 |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · nonDerivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,938 Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · nonDerivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · derivative · entry 11 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,477 Underlying: Class A Ordinary Share · 2,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · derivative · entry 10 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,222 Underlying: Class A Ordinary Share · 1,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · derivative · entry 9 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,221 Underlying: Class A Ordinary Share · 1,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 39,364 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · derivative · entry 8 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,364 Underlying: Class A Ordinary Share · 39,364 shares Expires 2035-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · derivative · entry 7 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,828 Underlying: Class A Ordinary Share · 9,828 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 2,819 | $33.49 | $94,408.31 |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · nonDerivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,425 Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,611 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023557 · form4-09032025_080909.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF CORP. & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 27,594 | $0.00 Strike: $13.35 | $0.00 |
DisclosureSEC source: 0001415889-25-015780 · form4-06052025_080613.xml · derivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 27,594 shares Expires 2029-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 27,594 | $29.02 | $800,777.88 |
DisclosureSEC source: 0001415889-25-015780 · form4-06052025_080613.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,415 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $29.00 and $29.115. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 27,594 | $13.35 | $368,379.90 |
DisclosureSEC source: 0001415889-25-015780 · form4-06052025_080613.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024. Read SEC document |
| May 05, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,272 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 10 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,389 Underlying: Class A Ordinary Share · 6,272 shares Expires 2033-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F10 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| May 05, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 6,272 | $28.00 | $175,616.00 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · nonDerivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,415 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.04. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 05, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,272 | $17.76 | $111,390.72 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| May 02, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 3,850 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 9 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,661 Underlying: Class A Ordinary Share · 3,850 shares Expires 2033-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F10 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| May 02, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 3,850 | $28.00 | $107,800.00 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,415 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 02, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 3,850 | $17.76 | $68,376.00 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 1,157 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 18 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,511 Underlying: Class A Ordinary Share · 1,157 shares Expires 2033-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F9 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 8,671 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 17 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,059 Underlying: Class A Ordinary Share · 8,671 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F8 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 13,406 | $0.00 Strike: $13.35 | $0.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 16 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,594 Underlying: Class A Ordinary Share · 13,406 shares Expires 2029-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.